Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis by Jianqiang Chen et al.
Chen et al. BMC Cancer 2014, 14:15
http://www.biomedcentral.com/1471-2407/14/15RESEARCH ARTICLE Open AccessSignificance of CD44 expression in head and neck
cancer: a systemic review and meta-analysis
Jianqiang Chen, Jianding Zhou, Jie Lu, Hua Xiong, Xueli Shi and Liang Gong*Abstract
Background: CD44 has been reported to be involved with tumor growth and metastasis and has also been
implicated as a CSC marker in head and neck squamous cell cancer (HNSCC). However, the prognostic value of
CD44 still remains controversial; hence, we investigated the correlation between CD44 and the clinicopathological
features of HNSCC by meta-analysis.
Methods: A comprehensive search was performed using PubMed, ISI web of Science and China National
Knowledge Infrastructure (CNKI) up to April 2013. Only studies with immunohistochemical staining of HNSCC were
considered. Data on TNM classification, tumor grade, disease free survival and 3- or 5-year overall survival rate were
extracted.
Results: Thirty studies with 2102 patients met the inclusion criteria for the meta-analysis. Fifteen studies used
anti-pan-CD44 antibody, 9 used anti-CD44-v6 antibody, 2 used anti-CD44-v3 and 2 used anti-CD44s antibody, 1
used anti-CD44-v9, and 1 used anti-CD44-v6,-v3 and -v4-5 simultaneously. The total percentage of CD44 expression
was 57.8%, with 49.3% in oral cancer patients, 66.4% in pharynx and 54.7% in larynx cancer patients expressing
CD44. No significant correlation between clinical features and CD44 expression was revealed for oral cancer
patients, but CD44 was shown to be associated with advanced T categories (larynx: RR = 1.33, 95% CI 1.01-1.76;
larynx & pharynx RR = 1.21, 95% CI 1.08-1.35), worse N categories (larynx: RR = 2.53, 95% CI 1.99-3.21; larynx &
pharynx RR = 1.95, 95% CI 1.35-2.82), higher tumor grades (larynx & pharynx RR = 1.71, 95% CI 1.04-2.79) and 5-year
OS rates (larynx: RR = 0.62, 95% CI 0.47-0.83; larynx & pharynx RR = 0.66, 95% CI 0.47-0.94) in patients with laryngeal
and pharyngolaryngeal cancer. In stratified analysis, pan-CD44 and CD44-v6 expression were both correlated with
5-year OS rate of patients with laryngeal (CD44: RR = 0.66, 95% CI 0.46-0.95; CD44-v6 RR = 0.53, 95% CI 0.37-0.77)
and pharyngolaryngeal cancer (CD44: RR = 0.56, 95% CI 0.34-0.93; CD44-v6 RR = 0.53, 95% CI 0.37-0.77).
Conclusions: Our analysis suggested that CD44 is related to worse T category, N category, tumor grade and
prognosis, in pharyngeal and laryngeal cancer, but no clear association was revealed between CD44 expression and
oral cancer.
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Although the treatment for head and neck cancer is im-
proving rapidly, head and neck cancer is still the sixth
most common cancer worldwide, mainly because it is usu-
ally difficult to diagnosis at an early stage [1]. The histo-
pathological types and developmental origins of cancers in
the head and neck (oral, pharynx and larynx) are highly
homologous, and ninety percent of the tumors in the head* Correspondence: 11118118@zju.edu.cn
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stated.and neck are squamous-cell carcinomas (HNSCCs), which
present as aggressive and recurrent malignancies [2].
Therefore, understanding the precise biological behav-
ior of HNSCC in the head and neck is very important
for early diagnosis and outcome prediction.
Currently, the most accepted prognostic factors are
TNM classification, which relies on the tumor size, and
metastasis [1]. However, the TNM system cannot distin-
guish aggressive tumors from nonaggressive tumors of
the same size. Therefore, it would be very beneficial to
find one or more bio-markers for the prediction of thetd. This is an Open Access article distributed under the terms of the Creative
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lation of cancer cells, referred to as cancer stem cells
(CSCs), was revealed to account for tumor initiation, re-
lapse and resistance to chemo- or radiotherapy; thus,
eradicating CSCs is considered critical in cancer therapy
[3,4]. The CSC hypothesis has also been coined for
HNSCC in the head and neck; some cell surface markers
have been reported as CSC markers in HNSCC cancers,
such as CD44, CD133, ALDH1 and ABCG2 [5-7], and
high expression of these markers is usually considered
an indicator of poor prognosis. Among them, CD44 is
the most reported CSC marker in HNSCC [8-10].
The CD44 receptor is a typeItransmembrane glycopro-
tein that was initially identified as a leukocyte antigen
[11,12]. The alternative splicing of variable exons of CD44
results in abundant variants, which are denoted CD44v,
and the isoform with no variable exons in the mRNA is
named CD44 standard (CD44s) [13]. The smallest, stand-
ard isoform is CD44s, which is generally expressed on ver-
tebrate cells, while CD44v is only expressed on some
epithelial cells [12,13]. CD44 is the major hyaluronan
(HA) receptor [14], and CD44 bound to HA has been
proven to participate in various tumor biological activities,
including tumor progression, metastasis and proliferation
[15,16]. CD44 plays a critical role in cell migration, with
involvement in multiple steps. Once activated, the cyto-
plasmic tail of CD44 interacts with the actin cytoskeleton,
and CD44 is induced to the leading edge of migrating
cells. Then, CD44 binds with CD62 on the endothelial
cells, and thereafter, the migrating cells roll on the endo-
thelial cells. This process is the initial step of cell migra-
tion called extravasation [12,17,18]. Although nearly all
evidence has shown a negative role of CD44 in tumor pro-
gression, some conflicting reports have found a positive
prognostic value of CD44 in head and neck cancers, espe-
cially in oral cancer [19-22], which indicates that some in-
formation regarding CD44 is still uncovered. Therefore,
we present here a systemic review and meta-analysis of
published studies on the association of CD44 expression
with clinicopathological features in patients with head and
neck cancer.
Methods
Literature search and eligibility criteria
A systematic literature search of the electronic data-
base PubMed, ISI Web of Science and China National
Knowledge Infrastructure (CNKI) up to April 2013 was
performed. A random combination of the following
terms was used for the search: ‘CD44’ , ‘oral’ , ‘larynx or
laryngeal’ , ‘pharynx, nasopharynx, oralpharynx, hypo-
pharynx or pharyngeal’ , and ‘tumor, neoplasm, cancer
or carcinoma’. The titles and abstracts of potential ref-
erences were manually examined to exclude irrelevant
publications, and all of the remaining literature on thetopic of interest was reviewed for additional pertinent
studies.
The studies included in this meta-analysis were either
randomized controlled studies (RCTs) or observational
studies (case-control or cohort) that evaluated the rela-
tionship between CD44 expression and clinicopathological
features or prognosis in head and neck cancer. Eligible
studies met the following criteria: (a) proven diagnosis of
HNSCC in head and neck (oral cavity, larynx or pharynx);
(b) the CD44-positive group was defined by an immuno-
histochemistry method; (c) the correlation of CD44 with
clinicopathological features and survival outcome (either
disease free survival or overall survival) was analyzed;
(d) HR/logHR and 95% confidence interval (CI)/standard
error (SE) or crude data were provided; and (e) the articles
were written in English or Chinese.
All information, including the titles and abstracts of
the potential literature, were read by two reviewers (L.G
and J.C) independently to exclude irrelevant publications.
Then, the full texts of the extracted articles were carefully
examined for comprehensive evaluation. Disagreements
were resolved by discussion with a third reviewer (J.Z).
Moreover, when multiple studies contained overlapping
data, the one with the largest data set or newest data was
included, and the others were excluded. Simultaneously,
the references of extracted articles were also manually
searched to avoid missing relevant studies. If the full text
was unavailable, we contacted the authors for the data
needed for the meta-analysis.
Data extraction and quality assessment
All data from the eligible studies were extracted by two
independent reviewers (J.Z and J.L) with a predefined
table (Additional file 1: Table S1). Data tables were de-
signed to extract all relevant data from texts, tables and
figures, including author, year, country, patient number,
detection method, duration of follow-up, T category, N
category, distant metastasis, the antibody used in the
article, positive rates of CD44 over-expression, disease free
survival rate (DFS) and 3-/5- year overall survival (OS)
rates. Because some articles showed survival data indir-
ectly with a Kaplan-Meier curve, the software GetData
Graph Digitizer 2.24 (http://getdata-graph-digitizer.com/)
was applied to digitize and extract the data.
The cut-off score of the CD44 positive group varied
among the different studies; we defined the CD44 positive
group according to the original articles. Because several
studies gave data on the 3-year survival outcome while
others gave data on 5-year survival outcome, we analyzed
both the 3-and 5-year overall survival rates here.
Statistical analysis
Stata version 11 (StataCorp LP, TX) was used in this meta-
analysis. The statistical process was performed according
Figure 1 Flow chart for the selection of included articles.
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vational Studies in Epidemiology group. Relative risk (RR)
with a 95% confidence interval (95% CI) was calculated
using Review Manager 4.2. The heterogeneity among the
studies was measured using the Q test and I2 test. A fixed
or random model was used depending on the hetero-
geneity analysis. The potential for publication bias was
assessed by the Funnel plots and Egger’s regression test.
P values < 0.05 were considered statistically significant.
All P values above are two tailed. Subgroup analyses
were performed to investigate the value of CD44 expres-
sion as a prognostic indicator for HNSCC patients in stud-
ies of different organs, geographical locations, sample sizes
and follow-up durations. Among the variants of CD44,
anti-pan-CD44 antibody and anti-CD44-v6 antibody were
the most applied in the articles; therefore, we also analyzed
all of the parameters stratified by pan-CD44 and CD44-v6.
Sensitivity analyses were also performed by excluding each
study individually. In addition, this meta-analysis was also
addressed with standard PRISMA checklist and diagram
(Additional files 2 and 3).
Results
Search results
Using the search strategy above, 474 articles were re-
trieved initially. After reviewing the titles and abstracts,
251 of those articles were excluded because they described
non-human experiments or non-head and neck cancer-
related studies or were non-original articles (reviews, let-
ters). Of the remaining articles, 169 were excluded because
they did not provide clinicopathological or survival rate
data. Then, a secondary screen was performed that ruled
out 24 studies without detailed data for analysis because,
for example, the numbers of patients with high and low
CD44 expression were not given. Eventually, a total of 30
studies were included in the present meta-analysis with
approximately 2102 participants (Figure 1).
Description of eligible studies
The characteristics of all included studies are listed in
Table 1. Among the 30 studies analyzed, 20 were
launched in Asia (China and Japan) and 10 in Europe or
the USA. A total of 2102 patients with a median cohort
size for each study of 58.5 (range 26 to 154) were in-
cluded, and the mean follow-up time for the studies was
68.5 months (range 36 - 271 months). The TNM stage
or tumor grade were reported in 24 studies, and patient
outcome was reported in 15 studies (DFS and OS were
presented in 5 and 12 articles, respectively). The median
percentage of patients with CD44 positive expression
was 57.8% (range 10.2 - 75.4%); for patients with oral
cancer, pharynx cancer, and larynx cancer, the median
percentages of patients with CD44 positive expression
were 49.3% (range 10.2 - 70.9%), 66.4% (57.5 - 75.4%)and 54.7% (12 - 82.9%), respectively. All studies applied
an immunochemistry staining method to detect CD44
expression: anti-pan-CD44 antibody was used in 15
studies [2,19-32], which detected all variations of CD44,
anti-CD44-v6 antibody was used in 9 studies [33-41],
anti-CD44-v3 antibody and anti-CD44s antibody were
used together in 2 studies [42-45], anti-CD44-v9 was
used in 1 study [46], and 1 study assessed CD44-v6,-v3
and -v4-5 simultaneously [47]. The most common cut-off
values designating CD44 expression were cell membrane
stainings of 50% (n = 16) and 25% (n = 5). Most of the in-
cluded patients received surgical therapy, while 50 patients
were treated with radiotherapy [21,42], 111 patients
were given combined radiotherapy and surgery, and two
patients received neoadjuvant chemotherapy [21,43].
Relationship of CD44 with clinical features and patient
survival
Additional file 4: Table S2 shows the summary RR of the
clinicopathological features in patients with CD44 high
and low expression. The pool analysis found a minimally
significant association between CD44 and clinical features;
the N grade (RR = 1.39, 95% CI 1.07-1.81) and 3-year OS
rate (RR = 0.76, 95% CI 0.59-0.99) were negatively cor-
related with CD44 expression. Egger's test did not show
any publication bias for the above data (Additional file 1:
Table S1). Because CD44 expression may be organ spe-
cific, we performed a stratified analysis of oral, larynx
and pharyngolaryngeal cancer. Although no significant
relationship was found between clinical features and
CD44 expression in oral cancer, CD44 expression was
shown to be associated with worse T categories (larynx:
RR = 1.33, 95% CI 1.01-1.76; larynx & pharynx RR = 1.21,
95% CI 1.08-1.35; Additional file 5: Figure S1), worse N
categories (larynx: RR = 2.53, 95% CI 1.99-3.21; larynx &
pharynx RR = 1.95, 95% CI 1.35-2.82; Additional file 6:
















N1 RR(95% CI) N2 RR(95% CI) N3 RR(95% CI) N4 RR(95% CI) N5 RR(95% CI) N6 RR(95% CI) N7 RR(95% CI)
Over all 13 1.15 (0.97, 1.35) 23 1.39 (1.07, 1.81) 4 1.79 (0.76, 4.26) 7 1.47 (1.00, 2.14) 5 1.50 (0.83, 2.71) 10 0.76 (0.59, 0.99) 12 0.76 (0.55, 1.05)
Cancer type
Oral 2 0.75 (0.48, 1.16) 9 0.82 (0.54, 1.25) 2 1.99 (0.99, 3.99) 2 0.91 (0.50, 1.67) 4 1.86 (1.47, 2.37) 3 0.85 (0.49, 1.47) 5 0.91 (0.46, 1.78)
Larynx 8 1.33 (1.01, 1.76) 11 2.53 (1.99, 3.21) - - 4 2.13 (0.99, 4.58) - - 5 0.87 (0.62, 1.23) 5 0.62 (0.47, 0.83)
Pharynx & Larynx 11 1.21 (1.08, 1.35) 14 1.95 (1.35, 2.82) 2 1.77 (0.13, 23.59) 5 1.71 (1.04, 2.79) 1 0.53 (0.29, 0.97) 7 0.72 (0.52, 0.99) 7 0.66 (0.47, 0.94)
Geographic area
Asia Over all 9 1.39 (1.17, 1.64) 16 1.81 (1.26, 2.61) 3 1.82 (0.59, 5.63) 6 1.61 (1.01, 2.57) 2 0.98 (0.28, 3.4) 4 0.71 (0.56, 0.89) 4 0.8 (0.57, 1.14)
Oral - 3 0.75 (0.10, 5.62) 1 2.03 (0.99, 4.17) 1 0.72 (0.02, 4.33) 1 1.87 (0.9, 3.88) - - - -
Larynx 6 1.60 (1.14, 2.25) 10 2.39 (1.65, 3.45) - - 4 2.13 (0.99, 4.58) - - 3 0.77 (0.66, 0.9) 3 0.69 (0.52, 0.91)
Larynx & pharynx 9 1.39 (1.17, 1.64) 13 1.98 (1.33, 2.95) 2 1.77 (0.13, 23.59) 5 1.71 (1.04, 2.79) 1 0.53 (0.29, 0.97) 4 0.71 (0.56, 0.89) 4 0.8 (0.57, 0.94)
Europe & USA Over all 3 0.88 (0.76, 1.02) 6 0.90 (0.68, 1.20) 1 1.46 (0.09, 22.93) 1 1.03 (0.56, 1.92) 2 3.08 (0.74, 12.78) 6 0.78 (0.48, 1.27) 8 0.64 (0.35, 1.16)
Oral 1 0.57 (0.30, 1.11) 5 0.73 (0.52, 1.02) 1 1.46 (0.09, 22.93) 1 1.03 (0.56, 1.92) 2 3.08 (0.74, 12.78) 3 0.85 (0.49, 1.47) 5 0.90 (0.46, 1.78)
Larynx 2 0.96 (0.85, 1.08) 1 1.85 (1.07, 3.18) - - - - - - 2 0.96 (0.24, 3.88) 2 0.46 (0.29, 0.72)
Larynx & pharynx 2 0.96 (0.85, 1.08) 1 1.85 (1.07, 3.18) - - - - - - 3 0.61 (0.15, 2.5) 3 0.36(0.23, 0.57)
Oral Pan-CD44 2 0.75 (0.48, 1.16) 3 0.58 (0.37, 0.92) 2 1.99 (0.99, 3.99) 2 0.91 (0.5, 1.67) 2 1.65 (1.68, 2.13) 3 0.85 (0.49, 1.47) 4 0.69 (0.32, 1.52)
CD44-6 - - 2 0.79 (0.29, 2.12) - - - - - - - - - -
Larynx Pan-CD44 5 1.25 (0.90, 1.73) 6 2.83 (2.01, 3.98) 2 - 4 2.13 (0.99, 4.58) - - 5 0.87 (0.62, 1.23) 3 0.66 (0.46, 0.95)
CD44-6 2 1.34 (0.99, 1.82) 4 1.92 (1.39, 2.64) - - - - - - - - 2 0.53 (0.37, 0.77)
Larynx & pharynx Pan-CD44 6 1.23 (0.92, 1.65) 7 2.74 (1.98, 3.81) 1 6.65 (0.93, 47.63) 4 2.13 (0.99, 4.58) 1 0.53 (0.29, 0.97) 6 0.794 (0.56, 1.1) 4 0.56 (0.34, 0.93)
CD44-6 3 1.15 (0.90, 1.48) 5 1.47 (0.90, 2.42) 1 1.03 (0.94, 1.13) - - - - - - 2 0.53 (0.37, 0.77)
Sample sizea <58.5 4 1.79 (0.82, 3.89) 10 1.388 (0.83, 2.33) 1 6.65 (0.93, 47.63) 3 1.34 (0.5, 3.58) 3 1.71 (0.44, 6.69) 3 0.34 (0.21, 0.54) 6 0.55 (0.22, 1.37)
≥58.5 9 1.03 (0.91, 1.17) 13 1.40 (1.01, 1.95) 3 1.62 (0.87, 3.03) 4 1.62 (0.91, 2.88) 2 1.65 (1.28, 2.13) 7 0.91 (0.69, 1.2) 6 0.80 (0.57, 1.13)
Follow time
(month)b
<68.5 7 1.04 (0.89, 1.20) 8 1.29 (0.80, 2.10) 2 4.51 (0.96, 21.13) 5 1.42 (0.96, 2.08) 5 1.50 (0.83, 2.71) 7 0.88 (0.66, 1.17) 8 0.89 (0.62, 1.28)
≥68.5 6 1.37 (0.94, 2.01) 15 1.45 (1.03, 2.05) 2 1.28 (0.36, 4.50) 2 1.27 (0.11,14.01) - - 3 0.39 (0.25, 0.62) 4 0.43 (0.29, 0.65)
a: median of sample size for each study.
b: median of follow-up time for each study.
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RR = 1.71, 95% CI 1.04-2.79; Additional file 7: Figure S3),
worse 3-year survival rates (larynx & pharynx RR = 0.72,
95% CI 0.52-0.99) and worse 5-year survival rates (larynx:
RR = 0.62, 95% CI 0.47 - 0.83; larynx & pharynx RR = 0.66,
95% CI 0.47 - 0.94; Figure 2) in laryngeal and pharyngolar-
yngeal cancer. Here, Egger's test showed that a publication
bias was present for the T category (larynx: p = 0.033;
larynx & pharynx: p = 0.033) and tumor grade (larynx &
pharynx: p = 0.01), but there was no evidence of publi-
cation bias for the 3-year (larynx & pharynx: Egger's test
p = 0.454; Begg's test p = 0.76) and 5-year overall survival
rates (larynx: Egger's test p = 0.137 Begg's test p = 1; larynx
& pharynx: Egger's test p = 0.355 Begg's test p = 0.548
Figure 3). Sensitivity analyses also revealed the stability
of our results (Additional file 8: Figure S4), indicating
that CD44 expression was a prognostic factor for laryngeal
and pharyngeal HNSCC patients .
Subgroup analyses
Additional file 4: Table S2 presents the detailed results
of the subgroup analyses. In addition to the analysis of
expression in specific organs, which was presented
above, we also evaluated the data of studies in different
geographic locations and the data of studies using differ-
ent antibodies. The results revealed that CD44 expres-
sion predicted worse 5-year OS in HNSCC patients of
the pharynx and larynx and that this result was similar
for the studies in Asia (RR = 0.8, 95% CI 0.57 - 0.94) and
Europe/USA (RR = 0.36, 95% CI 0.23 - 0.57). However,
CD44 expression was not found to be a significant pre-
dictor of 3-year OS in European patients (RR = 0.61, 95%
CI 0.15 - 2.5) as one Spanish study showed the oppositeFigure 2 CD44 expression and 5-year OS rate stratified to oral and phresult from the other European studies [20]. In consider-
ation of the clinical features, CD44 expression was also
associated with larger tumor size (RR = 1.39, 95% CI
1.17 - 1.64) and lymph node metastasis (RR = 1.98, 95% CI
1.33 - 2.95) in pharyngolaryngeal cancer of Asian patients;
however, this phenomenon was not found in European pa-
tients, which may due to the limited number of European
articles. Moreover, CD44 expression did not show signifi-
cant correlation with OS rate or any clinical characteristics
in Asian or European oral cancer patients. Because CD44
has many variants that have been reported with distinct
biological functions, we divided the studies into the anti-
pan-CD44 and anti-CD44-v6 subgroups, which were the
major antibodies applied in these studies, for each organ.
In oral cancer, pan-CD44 expression was not associated
with OS rate, but high CD44 level did predict a better DFS
rate (RR = 1.65, 95% CI 1.68 - 2.13) [21,42]. Furthermore,
a lower risk of lymph node metastasis was related with
pan-CD44 expression in oral cancer patients (RR = 0.58,
95% CI 0.37 - 0.92), but CD44-v6 expression did not
reveal a similar correlation (RR = 0.79, 95% CI 0.29 - 2.12).
On the other hand, pan-CD44 and CD44-v6 expression
were found to be related to higher N grade in laryngeal
cancer patients (pan-CD44, RR = 2.83, 95% CI 2.01 - 3.98;
CD44-v6 RR = 1.92 95% CI 1.39-2.64), but neither pan-
CD44 nor CD44-v6 expression showed a relationship with
T grade or tumor grade in laryngeal or pharyngolaryngeal
cancer patients (Additional file 4: Table S2). Furthermore,
a poorer 5-year OS rate was associated with pan-CD44
and CD44-v6 expression both in laryngeal (CD44: RR =
0.66, 95% CI 0.46 - 0.95; CD44-v6 RR = 0.53, 95% CI 0.37-
0.77) and pharyngolaryngeal cancer (CD44: RR = 0.56,
95% CI 0.34 - 0.93; CD44-v6 RR = 0.53, 95% CI 0.37-0.77).aryngolaryngeal cancer.
Figure 3 Begg’s test results of pharyngolaryngeal cancer patients'
5-year OS rate.
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the 3-year OS rate in patients with laryngeal cancer, which
implies that a longer follow-up time is needed for head
and neck patients.
Discussion
CD44 is one of the most frequently observed cancer
stem cell (CSC) markers in solid tumors, and it was re-
vealed to be a target of the Wnt pathway [48], which is
accepted as a main pathway for the stemness mainten-
ance of CSCs, and usually accepted as a poor prognosis
marker. However, most reports that used CD44 as a
CSC marker used the pan-CD44 antibody, which recog-
nizes all variants of CD44; thus, these studies provide
limited knowledge about the relationship between spe-
cific CD44 variants and CSCs. Very recently, several
studies found a distinct role between CD44v and CD44s.
The EMT process in several epithelial cells was accom-
panied by a transition in CD44 isoforms from CD44v to
CD44s, and CD44s has been shown to promote the
EMT process [49,50]. However, hypoxia and hypoxia-
inducible factor-1α have been shown to stimulate CD44v
expression, sialyl Lewis X glycan has been found to at-
tach to CD44v rather than to CD44s, and CD44v has
been shown to be a ligand for E-selectin during tumor
metastasis [51]. These findings indicate complicated
roles of CD44s and CD44v in tumor progression. The
expression of CD44 standard, v3, v5, v6, and v9 have
been reported in HNSCC patients [36,37,46,52,53]. Of
interest, we found that high CD44 expression in HNSCC
patients indicated different clinical values in the oral
cavity and pharynx or larynx. CD44 high expression
strongly predict poorer T grade, N grade and worse
overall survival rate in the larynx and pharynx, but bet-
ter disease free survival rate and no association with any
clinicopathological features in oral cancer. According toour systemic review results, CD44 expression may have
a different prognostic value in the squamous cancer of
the oral cavity and pharynx or larynx. To the best of our
knowledge, there is still no direct explanation for this
observation, so here, we mainly focused on the unex-
pected meta-analysis result and tried to give a rational
explanation by reviewing the literature.
Although many of these works showed a negative rela-
tionship between CD44 protein level and prognosis in
oral cancer patients, several reports found that an in-
creased transcriptional level of CD44 indicated disease
progression. Rajarajan et al. [54] found that the mRNA
level of CD44 was significantly increased in oral squamous
cell carcinomas; in addition, Lin et al. [55] revealed the
CD44 mRNA levels in the peripheral blood of patients
with locally advanced oral or oropharynx cancer were
much higher than in healthy people, and a high CD44
mRNA level was significantly related to poor prognosis.
This interesting phenomenon prompted us to review the
antibodies applied by all of the studies in this meta-
analysis. As different CD44 isoforms have distinct extra-
cellular domains while retaining the same transmembrane
and intracellular domain structure, nearly all works in this
review used antibodies that targeted the extracellular
domain of CD44. It is important to note that decreased
intensity of CD44 by extracellular domain targeted anti-
body detection does not definitively indicate low CD44
expression because the shedding of CD44, which means
the cutting off of the extracellular domain of CD44,
could cause the false appearance of decreased CD44
expression. In fact, CD44 shedding has been observed
in many human tumors, including breast, lung, colon
and ovarian carcinomas [56], and indeed takes part in
tumorigenesis and tumor metastasis. In the late phase
of HA-CD44 binding, the CD44 at the leading edge of
the cell is cleaved by a disintegrin and metalloproteinase
domain (ADAM) protein and matrix metalloproteinase
14 (MMP14), and this cleavage is required for tumor
cell migration [57]. Furthermore, researchers have found
that the CD44 ectodomain cleavage subsequently induces
the CD44 intramembranous cleavage, and the intramem-
branous cleavage generates the CD44 intracellular domain,
which is translocated to the nucleus as a signal transduc-
tion molecule and activates the transcription of various
genes, including CD44 [58,59]. This positive feedback loop
supports our hypothesis that an increase in CD44 expres-
sion during oral cancer progression could be covered by
its shedding.
The shedding of CD44 has been reported to be mainly
associated with ADAM10 and ADAM17. ADAM10 is
co-localized with CD44, and inhibition of ADAM10 could
decrease the shedding of CD44 [60]. In oral cancer, it was
shown that ADAM10 and ADAM17 expression were
positively related to CD44 cleavage status; furthermore,
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cancer and were indicators of nodal metastasis [61-63].
However, little research on ADAM 10/17 could be found
for pharyngolaryngeal cancer; therefore, we referred to
the Oncomine database (www.oncomine.org). The results
showed that, according to gene microarray analysis,
ADAM10 was not increased in hypopharyngeal cancer
compared to normal tissue [64] and that both ADAM10
and ADAM17 were not presented in the list of genes with
significantly altered expression levels in pharyngolaryngeal
cancer compared to normal tissue. Although these results
were based on mRNA levels, they could also strongly indi-
cate a difference in CD44 proteolytic enzyme expression
between oral and pharyngolaryngeal cancer and may ex-
plain the different role of CD44 in the oral cavity and
pharynx. With this in mind, we propose that future studies
should evaluate the cleavage of CD44 rather than intact
CD44 protein for prognosis prediction.
According to the analysis above, CD44 indeed partici-
pates in oral cancer progression, but cell staining of CD44
may not be accurate enough to reflect the authentic levels
of CD44 because of the shedding of CD44. CD44 cleavage
results in the extracellular epitope of CD44 being detached
from the cell membrane and existing in its soluble form
(sCD44). Although CD44 was widely expressed in normal
oral mucosa, CD44 cleavage was found to occur at a low
level or not at all in normal oral mucosa [65] and to be
overexpressed in oral cancer tissue [61], which could be
explained by the proteolytic effect of ADAM. Additionally,
it was reported that the salivary sCD44 levels were much
higher in HNSCC patients than in patients with benign
disease [66,67]; however, the plasma level of sCD44 was
not significantly different between oral cancer patients and
normal controls, which may be attributed to the relatively
small burden of oral tumors that may not alter the basal
level of CD44 [66]. The same situation has been reported
in gastrointestinal stromal tumors (GIST); CD44 cleavage
activity was shown in 87.1% of GISTs but was absent in
normal tissues, and increased CD44 cleavage was signifi-
cantly related to advanced TNM stage and poor prognosis
[68]. Here, we proposed that detecting the CD44 cleavage
or soluble CD44 levels in tissue sections or oral rinses
would be better than cell staining for prognostic predic-
tion; another advantage of oral rinses is their convenience
and noninvasiveness. Furthermore, based on the above
discussion, CD44 may have limited utility in identifying
oral CSCs [69], but some other cell surface markers have
been reported to be expressed on stem-like cells in oral
cancer, such as CD133, ABCG2 and ALDH1 [5,6]. In
contrast, high CD44 expression was proven to be closely
related to poor prognosis and was clearly enriched in
stem-like cells in pharyngeal or laryngeal cancers [70-72].
Although we performed a comprehensive analysis of
the association between CD44 expression and patientclinicopathological parameters for HNSCC, there were
some limitations to this meta-analysis. First, the con-
founders were hard to control in the case-control studies,
which may have affected the authentic prognostic value
of CD44 expression. Second, except for CD44-v6, our
systematic review and meta-analysis could not clarify
the association between other CD44 variants and patient
survival because of insufficient eligible information. Third,
high quality studies with complete reports, including
TNM stage and survival data, were limited, which may
compromise our conclusions. In addition, there could be
potential language bias in this meta-analysis because we
only considered the literature written in English and
Chinese. In conclusion, our systematic review and
meta-analysis suggested that cell staining of CD44 has
different prediction values for oral and pharyngolaryn-
geal cancer. In pharyngolaryngeal cancer, high CD44
staining intensity indicated worse T grade, worse N
grade and a markedly shortened OS; meanwhile, cell
staining of CD44 is not recommended for any clinico-
pathological or survival prediction for oral squamous
cancer patients based on our review. The sCD44 evalu-
ation may be a good substitute in oral cancer patients,
and additional well-designed studies are needed to draw
an authentic conclusion.Conclusion
Our analysis indicated prognostic value of CD44 expres-
sion were different between laryngopharyngeal cancer
and oral cancer, that CD44 related to worse T category,
N category, tumor grade and prognosis in pharyngeal
and laryngeal cancer, but no significant association was
revealed between CD44 and oral cancer.Additional files
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